Literature DB >> 23155256

EVI1 and MDS1/EVI1 expression during primary human hematopoietic progenitor cell differentiation into various myeloid lineages.

Katarina Steinleitner1, Paulina Rampetsreiter, Rene Köffel, Gajalakshmi Ramanathan, Christine Mannhalter, Herbert Strobl, Rotraud Wieser.   

Abstract

BACKGROUND AND AIM: Overexpression of ecotropic viral integration site 1 (EVI1) is associated with aggressive disease in myeloid leukemia. We therefore studied its expression and function in cluster of differentiation 34-positive (CD34(+)) primary human hematopoietic progenitor cells.
MATERIALS AND METHODS: CD34(+) cells were differentiated into various myeloid lineages using the appropriate cytokines. EVI1 expression was measured by quantitative real time reverse transcriptase-polymerase chain reaction (qRT-PCR) and intranuclear fluorescence-activated cell sorting (FACS). Experimental manipulation of EVI1 levels was achieved using retroviral infection.
RESULTS: EVI1 mRNA and its variant myelodysplastic syndrome 1 (MDS1)/EVI1, which gives rise to a partially antagonistic protein, were detectable in CD34(+) cells, but their levels declined rapidly during differentiation into the granulocyte, monocyte, dendritic, erythroid, and megakaryocyte lineages. Similarly, EVI1 protein levels decreased during myeloid differentiation. Attempts to experimentally express EVI1 in CD34(+) and U937 cells indicated that ectopic expression of EVI1 may cause growth arrest, apoptosis and/or senescence of human hematopoietic cells.
CONCLUSION: EVI1 is expressed in human hematopoietic progenitor cells, but is down-regulated during differentiation. Ectopic expression of EVI1 may activate cellular safeguards against oncogene activation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23155256      PMCID: PMC3605800     

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  26 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  In vitro expansion of human cord blood CD36+ erythroid progenitors: temporal changes in gene and protein expression.

Authors:  Marshall S Scicchitano; David C McFarland; Lauren A Tierney; Padma K Narayanan; Lester W Schwartz
Journal:  Exp Hematol       Date:  2003-09       Impact factor: 3.084

3.  Methylation and silencing of miRNA-124 by EVI1 and self-renewal exhaustion of hematopoietic stem cells in murine myelodysplastic syndrome.

Authors:  Jerome Dickstein; Vitalyi Senyuk; Kavitha Premanand; Leopoldo Laricchia-Robbio; Peng Xu; Francesca Cattaneo; Raffaella Fazzina; Giuseppina Nucifora
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-06       Impact factor: 11.205

4.  Oncogenic transcription factor Evi1 regulates hematopoietic stem cell proliferation through GATA-2 expression.

Authors:  Hiromi Yuasa; Yuichi Oike; Atsushi Iwama; Ichiro Nishikata; Daisuke Sugiyama; Archibald Perkins; Michael L Mucenski; Toshio Suda; Kazuhiro Morishita
Journal:  EMBO J       Date:  2005-05-12       Impact factor: 11.598

Review 5.  A node between proliferation, apoptosis, and growth arrest.

Authors:  M V Blagosklonny
Journal:  Bioessays       Date:  1999-08       Impact factor: 4.345

6.  EVI1 is expressed in megakaryocyte cell lineage and enforced expression of EVI1 in UT-7/GM cells induces megakaryocyte differentiation.

Authors:  Seiichi Shimizu; Toshiro Nagasawa; Osamu Katoh; Norio Komatsu; Jun Yokota; Kazuhiro Morishita
Journal:  Biochem Biophys Res Commun       Date:  2002-04-05       Impact factor: 3.575

7.  High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated.

Authors:  Sanne Lugthart; Ellen van Drunen; Yvette van Norden; Antoinette van Hoven; Claudia A J Erpelinck; Peter J M Valk; H Berna Beverloo; Bob Löwenberg; Ruud Delwel
Journal:  Blood       Date:  2008-02-13       Impact factor: 22.113

8.  Significant increase of self-renewal in hematopoietic cells after forced expression of EVI1.

Authors:  Leopoldo Laricchia-Robbio; Giuseppina Nucifora
Journal:  Blood Cells Mol Dis       Date:  2007-10-29       Impact factor: 3.039

9.  Down-regulation of RXRalpha expression is essential for neutrophil development from granulocyte/monocyte progenitors.

Authors:  Sabine Taschner; Christina Koesters; Barbara Platzer; Almut Jörgl; Wilfried Ellmeier; Thomas Benesch; Herbert Strobl
Journal:  Blood       Date:  2006-10-03       Impact factor: 22.113

10.  The increased expression of integrin α6 (ITGA6) enhances drug resistance in EVI1(high) leukemia.

Authors:  Norio Yamakawa; Kazuko Kaneda; Yusuke Saito; Emi Ichihara; Kazuhiro Morishita
Journal:  PLoS One       Date:  2012-01-25       Impact factor: 3.240

View more
  10 in total

1.  EVI1-rearranged acute myeloid leukemias are characterized by distinct molecular alterations.

Authors:  Vincent-Philippe Lavallée; Patrick Gendron; Sébastien Lemieux; Giovanni D'Angelo; Josée Hébert; Guy Sauvageau
Journal:  Blood       Date:  2014-10-20       Impact factor: 22.113

2.  Identification of Hematopoietic Stem Cell Engraftment Genes in Gene Therapy Studies.

Authors:  John M Powers; Grant D Trobridge
Journal:  J Stem Cell Res Ther       Date:  2013-09-01

3.  EVI1 promotes tumor growth via transcriptional repression of MS4A3.

Authors:  Gerwin Heller; Anna Rommer; Katarina Steinleitner; Julia Etzler; Hubert Hackl; Petra Heffeter; Erwin Tomasich; Martin Filipits; Birgit Steinmetz; Thais Topakian; Simone Klingenbrunner; Barbara Ziegler; Andreas Spittler; Sabine Zöchbauer-Müller; Walter Berger; Rotraud Wieser
Journal:  J Hematol Oncol       Date:  2015-03-21       Impact factor: 17.388

Review 4.  All-trans retinoic acid in non-promyelocytic acute myeloid leukemia: driver lesion dependent effects on leukemic stem cells.

Authors:  Chi H Nguyen; Alexander M Grandits; Louise E Purton; Heinz Sill; Rotraud Wieser
Journal:  Cell Cycle       Date:  2020-09-08       Impact factor: 4.534

Review 5.  EVI1 dysregulation: impact on biology and therapy of myeloid malignancies.

Authors:  Christine Birdwell; Warren Fiskus; Tapan M Kadia; Courtney D DiNardo; Christopher P Mill; Kapil N Bhalla
Journal:  Blood Cancer J       Date:  2021-03-22       Impact factor: 11.037

6.  A clinical study on the factors associated with nasopharyngeal carcinoma among the Chinese population.

Authors:  Zhenfang Gu; Dongyu Hu; Wei Cui; Haiying Liu; Chunmei Zhang
Journal:  Exp Ther Med       Date:  2021-02-19       Impact factor: 2.447

7.  EVI1 Promotes the Proliferation and Invasive Properties of Human Head and Neck Squamous Cell Carcinoma Cells.

Authors:  Alexander Michael Grandits; Sophie Bromberger; Gerwin Heller; Barbara Andrea Reinoehl; Erwin Tomasich; Klaudia Schossleitner; Anna Sophie Berghoff; Thorsten Fuereder; Rotraud Wieser
Journal:  Int J Mol Sci       Date:  2022-01-19       Impact factor: 5.923

8.  NKL Homeobox Gene VENTX Is Part of a Regulatory Network in Human Conventional Dendritic Cells.

Authors:  Stefan Nagel; Claudia Pommerenke; Corinna Meyer; Hans G Drexler
Journal:  Int J Mol Sci       Date:  2021-05-31       Impact factor: 5.923

9.  EVI1 inhibits apoptosis induced by antileukemic drugs via upregulation of CDKN1A/p21/WAF in human myeloid cells.

Authors:  Anna Rommer; Birgit Steinmetz; Friederike Herbst; Hubert Hackl; Petra Heffeter; Daniela Heilos; Martin Filipits; Katarina Steinleitner; Shayda Hemmati; Irene Herbacek; Ilse Schwarzinger; Katharina Hartl; Pieter Rondou; Hanno Glimm; Kadin Karakaya; Alwin Krämer; Walter Berger; Rotraud Wieser
Journal:  PLoS One       Date:  2013-02-14       Impact factor: 3.240

10.  The oncogene EVI1 enhances transcriptional and biological responses of human myeloid cells to all-trans retinoic acid.

Authors:  Birgit Steinmetz; Hubert Hackl; Eva Slabáková; Ilse Schwarzinger; Monika Smějová; Andreas Spittler; Itziar Arbesu; Medhat Shehata; Karel Souček; Rotraud Wieser
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.